

CITATION REPORT

List of articles citing

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

DOI: 10.4065/81.8.1047

Mayo Clinic Proceedings, 2006, 81, 1047-53.

Source: <https://exaly.com/paper-pdf/39713100/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
213	TREATMENT OF MYELOMA-RELATED COMPLICATIONS. 76-85		
212	Novel approaches in the management of myeloma-related skeletal complications. 2006 , 4, 15-8		6
211	Bisphosphonate complications including osteonecrosis of the jaw. 2006 , 2006, 356-60, 515		58
210	Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. 2007 , 203, 641-4		29
209	Monoclonal gammopathy of undetermined significance. 2007 , 356, 2223-4; author reply 2223-4		2
208	Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. 2007 , 47, 942-50		22
207	Myeloma bone disease and proteasome inhibition therapies. 2007 , 110, 1098-104		120
206	Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditions. 2007 , 99, 986-7		8
205	Myeloma update. 2007 , 11, 231-9		11
204	Osteonecrosis of the jaw related to the use of bisphosphonates. 2007 , 19, 315-22		62
203	Bibliography. Current world literature. Cardiac and circulatory problems. 2007 , 1, 328-46		
202	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-341	6.4	119
201	Cancer Symposium for the Practitioner: Introduction to Solid Tumors. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 107-109	6.4	4
200	Mayo Clinic Proceedings 2007: Enriching Our Service to Authors and Readers. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 16-19	6.4	3
199	A Potential Anatomic Cause of Mandibular Osteonecrosis in Patients Receiving Bisphosphonate Treatment. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 134	6.4	1
198	Giant Cell Arteritis and Polymyalgia RheumaticaReply <i>Mayo Clinic Proceedings</i> , 2007 , 82, 133-134	6.4	0
197	Medical management update: multiple myeloma. 2007 , 103, 599-609		28

196	Bisphosphonates and jaw osteonecrosis: the UAMS experience. 2007 , 136, 396-400		38
195	Optimal management of metastatic bone disease. 2007 , 11 Suppl 2, S32-7		17
194	Giant Cell Arteritis and Polymyalgia Rheumatica Reply <i>Mayo Clinic Proceedings</i> , 2007 , 82, 133-134	6.4	
193	Bisphosphonate-induced osteonecrosis of the jaw. 2007 , 41, 276-84		39
192	Complications of myeloma therapy. 2007 , 21, 1247-73, xi		3
191	The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. 2007 , 25, 913-33		50
190	Osteonecrosis of the jaws and bisphosphonate therapy. 2007 , 86, 1013-21		115
189	American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. 2007 , 25, 2464-72		350
188	Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 516-7; author reply 517-8	6.4	51
187	A potential anatomic cause of mandibular osteonecrosis in patients receiving bisphosphonate treatment. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 134; author reply 134-5	6.4	1
186	Expanding the Journal's Circulation to Oncologists A New Dimension for Mayo Clinic Proceedings. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 915-916	6.4	0
185	Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-41	6.4	123
184	Complications of multiple myeloma. 2007 , 21, 1231-46, xi		55
183	Mayo Clinic Proceedings 2007: Enriching our service to authors and readers. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 16-9	6.4	3
182	Cancer symposium for the practitioner: introduction to solid tumors. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 107-9	6.4	5
181	Pathophysiology of myeloma bone disease. 2007 , 20, 613-24		46
180	Supportive care in multiple myeloma. 2007 , 20, 817-35		24
179	The safety of zoledronic acid. 2007 , 6, 305-13		26

178	Literature Survey. 2007 , 235-258	
177	Current Awareness in Hematological Oncology. 2007 , 25, 44-51	
176	Treatment strategies for bone disease. 2007 , 40, 1139-46	30
175	A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. 2007 , 21, 1545-8	82
174	Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase. 2007 , 21, 1596-9	1
173	The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. 2007 , 21, 1875-84	75
172	Multiple myeloma: charging toward a bright future. 2007 , 57, 301-18	63
171	Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. 2007 , 79, 69-71	28
170	Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates. 2007 , 65, 1440-1	9
169	Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. 2007 , 131, 311-20	54
168	Cancer-associated bone disease. 2007 , 5, 120-7	18
167	Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. 2008 , 4, 123-7	35
166	[Bisphosphonate-associated osteonecrosis of the jaw]. 2008 , 120, 467-76	3
165	Pattern of intravenous bisphosphonate use in outpatient care in Germany. 2008 , 17, 896-903	8
164	Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. 2008 , 66, 987-94	177
163	Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. 2008 , 44, 857-69	198
162	Biophosphonate-related osteonecrosis of the jaws. 2008 , 52, 111-28, ix	51
161	Is Cure Essential in the Treatment of Cancer?. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1413-1414	6.4 2

160	The need for adequate coverage of oncology topics in internal medicine journals. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 980-2	6.4	
159	Bisphosphonates: mechanism of action and role in clinical practice. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1032-45	6.4	829
158	Treatment of myeloma: cure vs control. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1142-5	6.4	58
157	Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. 2008 , 7, 491-512		34
156	Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment. 2008 , 3, 1-10		2
155	Bisphosphonate-related osteochemonecrosis of the jaws. 2008 , 69, 158-62		2
154	The biomechanics of vertebroplasty in multiple myeloma and metastatic bladder cancer: a preliminary cadaveric investigation. 2008 , 9, 493-501		16
153	Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. 2008 , 358, 1283-91		41
152	Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. 2008 , 14, 2387-95		114
151	DIAGNOSIS AND TREATMENT OF MYELOMA BONE DISEASE. 64-75		1
150	The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. 2008 , 20, 155-61		27
149	Lesão lítica de mandíbula em mulher com mieloma múltiplo usuária de bisfosfonato. 2008 , 48,		
148	Current and emerging treatments for multiple myeloma. 2008 , 14, 12-9		19
147	Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians. 2008 , 14, 1150-68		8
146	Front line treatment of elderly multiple myeloma in the era of novel agents. <i>Biologics: Targets and Therapy</i> , 2008 , 99	4.4	
145	Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients. 2008 , 4, 1371-4		
144	Pharmacotherapy with Pamidronate Disodium of Osteolytic Bone Metastases of Breast Cancer, Osteolytic Lesions of Multiple Myeloma, and Paget's Disease. 2009 , 1, CMT.S2166		
143	Medical treatment of hypercalcaemia. 2009 , 8, 83-95		23

142	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. 2009 , 20, 1303-17	171
141	High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 2009 , 15, 5829-39	70
140	Bisphosphonates in oncology: rising stars or fallen heroes. 2009 , 14, 181-91	25
139	Bisphosphonates--role in cancer therapies. 2009 , 67, 19-26	14
138	Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw. 2009 , 67, 1373-7	25
137	Multiple myeloma presenting as mandibular ill-defined radiolucent lesion with numb chin syndrome: a case report. 2009 , 67, 1991-6	19
136	Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. 2009 , 83, 279-89	43
135	Effects of bortezomib on bone disease in multiple myeloma. 2009 , 84, 1-2	6
134	Multiple myeloma. 2009 , 33, 7-64	59
133	Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. 2009 , 89, 259-268	24
132	The role of bisphosphonates in multiple myeloma. 2009 , 4, 108-12	16
131	References. 2009 , 44, 537-557	1
130	Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate. 2009 , 104, 384-92	27
129	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. 2009 , 39, 304-16	36
128	Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. 2009 , 71, 12-21	28
127	Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. 2009 , 15, 1143-238	1223
126	Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK. 2009 , 7, 18-23	13
125	Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. 2009 , 60, 85-96	73

124	Osseous metastases: drugs that enhance bone integrity and prevent adverse skeletal events. 2009 , 10, 723-6	2
123	Management of complications in multiple myeloma. 2009 , 46, 176-89	22
122	[Osteonecrosis of the jaw and biphosphonates: imaging features]. 2009 , 90, 199-205	4
121	How I treat multiple myeloma in younger patients. 2009 , 114, 5436-43	116
120	Bisphosphonate therapy in the treatment of multiple myeloma. 2010 , 16, 3028-36	5
119	Bisphosphonate-related osteonecrosis of the jaw: tip of the iceberg. 2010 , 21, 25-32	14
118	Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. 2010 , 25, 98-105	66
117	Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. 2010 , 66, 547-54	32
116	Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases. 2010 , 9, 1-12	2
115	Supportive Therapie bei multiplem Myelom. 2010 , 16, 298-308	
114	Treatment of newly diagnosed multiple myeloma: advances in current therapy. 2010 , 27 Suppl 1, S14-24	9
113	Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. 2010 , 84, 412-20	22
112	First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. 2010 , 85, 290-9	42
111	Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. 2010 , 25, 2582-91	29
110	Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. 2010 , 151, 92-3	4
109	Myeloma Bone Disease. 2010 ,	2
108	[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]. 2010 , 134, 268-78	5
107	Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. 2010 , 14, 205-10	5

106	Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists. 2010 , 36, 541-5	5
105	Zoledronic acid in myeloma: MRC Myeloma IX. 2010 , 376, 1965-6	10
104	The role of bisphosphonate therapy in the global management of multiple myeloma. 2011 , 52, 736-7	1
103	Advances in imaging and the management of myeloma bone disease. 2011 , 29, 1907-15	95
102	[Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma]. 2011 , 32, 494-505	5
101	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. 2011 , 12, 743-52	133
100	A review of the clinical implications of bisphosphonates in dentistry. 2011 , 56, 2-9	55
99	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. 2011 , 11, 593-603	26
98	Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. 2011 , 48, 55-65	15
97	Bone Complications of Myeloma and Lymphoma. 417-424	
96	Bisphosphonate-related osteonecrosis of the jaw: an overview. 2011 , 1218, 38-46	83
95	DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by Γ lymphocytes. 2011 , 118, 2743-51	60
94	Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. 2011 , 22, 693-702	53
93	Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?. 2011 , 77 Suppl 1, S24-30	7
92	Multiple Myeloma. 2011 ,	2
91	The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. 2011 , 16, 651-62	47
90	Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases. 2011 , 93, e106	11
89	Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. 2012 , 119, 5374-83	105

88	Tumor-assoziierte Osteopathien: Diagnostik und Therapie. 2012 , 15, 22-33	
87	Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. 2012 , 35, 658-64	29
86	Bisphosphonate-related osteonecrosis of the jaws--a review. 2012 , 48, 938-947	97
85	Prevention and treatment of myeloma bone disease. 2012 , 7, 249-57	10
84	Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. 2012 , 7, e41065	18
83	Use of Bisphosphonates in Hematology. 2012 , 35-48	
82	Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. 2012 , 87, 490-5	15
81	Drug-induced osteonecrosis of the jaw. 2012 , 5, 57-62	2
80	Osteoporosis and osteopenia: implications for periodontal and implant therapy. 2012 , 59, 111-39	31
79	Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone. 2013 , 71, 1017-26	30
78	Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. 2013 , 19, 504-11	15
77	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 2013 , 31, 2347-57	245
76	Cancer-associated bone disease. 2013 , 24, 2929-53	86
75	Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data. 2013 , 11, 113-121	4
74	Complications and Special Presentations of Plasma Cell Myeloma. 2013 , 665-680	1
73	Diagnosis and Treatment of Multiple Myeloma. 2013 , 637-663	2
72	Evaluation of the Patient at Risk for Osteoporosis. 2013 , 1481-1504	2
71	Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy). 2013 , 2013, 672027	10

70	How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). 2013 , 121, 3085-94	60
69	Multiple myeloma: an update. 2013 , 28, 3-11	24
68	Bone health in cancer patients: ESMO Clinical Practice Guidelines. 2014 , 25 Suppl 3, iii124-37	342
67	State of oral mucosa as an additional symptom in the course of primary amyloidosis and multiple myeloma disease. 2014 , 2014, 293063	2
66	Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. 2014 , 166, 109-17	23
65	The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. 2014 , 26, 231-7	6
64	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. 2014 , 32, 587-600	255
63	Multiple Myeloma. 2014 ,	9
62	Management of bone disease in multiple myeloma. 2014 , 7, 113-25	73
61	unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?. 2014 , 29, 2529-33	37
60	Bisphosphonates in multiple myeloma: a fractured consensus. 2015 , 56, 553-4	1
59	Bone metastases [Current status of bone-targeted treatments]. 2015 , 677-683	
58	Handbook of Multiple Myeloma. 2015 ,	3
57	Multiple myeloma. 2015 , 385, 2197-208	401
56	Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures. 2016 , 4,	2
55	Zoledronate induces autophagic cell death in human umbilical vein endothelial cells via Beclin-1 dependent pathway activation. 2016 , 14, 4747-4754	8
54	Current Controversies in the Management of Myeloma Bone Disease. 2016 , 231, 2374-9	26
53	Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. 2016 , 19, 477-86	16

52	Bone Disease in Myeloma: The Claws of CRAB. 2016 , 22, 1301-3		1
51	Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?. <i>Supportive Care in Cancer</i> , 2017 , 25, 345-349	3.9	14
50	Prise en charge des lésions osseuses du myélome multiple : quelles particularités ?. 2017 , 84, 197-204		
49	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. 2017 , 47, 938-951		13
48	Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. 2018 , 27, e12638		5
47	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. 2019 , 137, 18-26		8
46	Multiple Myeloma and Related Disorders. 2020 , 1884-1910.e7		2
45	Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. 2020 , 105, 434-448		
44	Changing face of medication-related osteonecrosis of the jaw: Sheba Medical Center experience-fifteen years. 2020 , 38, 819-825		0
43	Supportive Care in Multiple Myeloma. 2020 , 15, 56-61		4
42	The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. 2020 , 26, 1180-1189		0
41	Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study. 2021 , 100, 1079-1085		3
40	PREVENTION AND SCREENING OF OSTEONECROSIS OF JAW (ONJ) IN MYELOMA PATIENTS : A MONOISTITUTIONAL FIFTEEN-YEAR EXPERIENCE.		
39	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. 2021 ,		0
38	Evaluation of the osteoporosis patient. 2021 , 1475-1500		2
37	Biphosphonates In The Management Of Metastatic Bone Disease. 2009 , 195-231		1
36	Supportive therapy in multiple myeloma. 2011 , 183, 307-33		2
35	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. 2017 , 58, 55-71		4

- 34 Osteonecrosis of the jaw associated with bisphosphonate therapy. **2009**, 32, 900 5
- 33 [Bisphosphonate treatment of osteoporosis and other skeletal diseases]. **2011**, 131, 244-7 3
- 32 Therapeutic Dimensions of Bisphosphonates: A Clinical Update. **2020**, 11, 166 3
- 31 Low Testosterone: An Important Predictor of Low Mineral Bone Density in Young Men: Our Own Experience and a Review of Literature. **2013**, 03, 19-33 3
- 30 Supportive care in multiple myeloma: Current practices and advances. **2021**, 29, 100476
- 29 Bisphosphonates for metastatic bone disease [too much of a good thing?]. **2006**, 3, 24-27
- 28 Multiple Myeloma and Related Disorders. **2008**, 2323-2351 1
- 27 Skeletal Metastases: Optimal Management Today. **2009**, 17-32
- 26 Multiple Myeloma and Other Hematological Malignancies of Bone. **2010**, 43-56
- 25 Osteonecrosis of the Jaw. **2010**, 133-149
- 24 Bisphosphonates in the Treatment of Myeloma Bone Disease. **2010**, 117-132
- 23 Multiple Myeloma. 577-598
- 22 Multiple Myeloma: Molecular Biology, Diagnosis and Treatment. 315-341
- 21 Multiple Myeloma Surveillance Counterpoint: Canada. **2013**, 503-509
- 20 Ostéonécroses des maxillaires dues aux bisphosphonates administrés par voie intraveineuse : incidence et facteurs de risque. **2013**, 19, 21-31 2
- 19 Treatment and Prevention of Bone Metastases and Myeloma Bone Disease. 741-753 1
- 18 Bisphosphonate-Associated Osteonecrosis of the Jaws. 929-940
- 17 Management of Treatment Complications and Supportive Care. **2014**, 159-177

16	Biology and Treatment of Skeletal Manifestations in Multiple Myeloma. 2014 , 05, 387-402		
15	Multiple Myeloma and Related Disorders. 2014 , 1991-2017.e7		1
14	Bisphosphonate and Denosumab Therapy: Fields of Application. 2015 , 17-26		
13	Bone disease. 2015 , 79-90		
12	Therapie der tumorinduzierten Hyperkalzämie und der tumorinduzierten Osteolyse. 1448-1471		
11	Front line treatment of elderly multiple myeloma in the era of novel agents. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 99-109	4.4	5
10	Osteonecrosis of the myeloma patients treated with bisphosphonates. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2007 , 4, 43-7		2
9	Prevention of bisphosphonates-induced osteonecrosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2007 , 4, 58-61		2
8	Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2007 , 4, 37-42		33
7	Soluble molecules and bone metabolism in multiple myeloma: a review. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2008 , 5, 67-70		1
6	Multiple Myeloma presenting as sacroiliac joint pain: a case report. <i>Journal of the Canadian Chiropractic Association</i> , 2012 , 56, 94-101	0.6	2
5	Bisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing. <i>Journal of the Advanced Practitioner in Oncology</i> , 2013 , 4, 25-35	0.7	1
4	Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019 , 36, S22-S26	0.7	1
3	Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.. <i>Supportive Care in Cancer</i> , 2022 ,	3.9	1
2	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. 155-183		
1	The use of bone-modifying agents in multiple myeloma. 2022 , 100999		